Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Jan 30, 2017
- Appointment signals clinical focus - LEXINGTON, Mass., Jan. 30, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Jean-Marie Cuillerot, M.D.
Nov 14, 2016
LEXINGTON, Mass., Nov. 14, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ:  AGEN ), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today announced that the Company will present at the Jefferies 2016 London
Oct 27, 2016
Company to host conference call at 11:00 a.m. ET today LEXINGTON, Mass. , Oct. 27, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today provided an update
Jul 28, 2016
Company to host conference call at 11:00 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and
Jun 15, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present
Jun 08, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00
Jun 02, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B.
May 19, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Ulf Wiinberg to the Company’s Board of Directors.
Apr 28, 2016
Company to host conference call at 11am ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today provided a corporate update and reported financial results for the first quarter ended March 31,
Mar 30, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced participation at the following conferences: The 6 th  Annual William Blair and Maidstone Life Sciences conference “Cancer
Mar 01, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced that Garo Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, R&D at Agenus will present at the   Cowen